High prevalence of multidrug-resistant tuberculosis, Swaziland, 2009-2010

Emerging Infectious Diseases

Volumn 18, Issue 1, 2012, Pages 29-37

  Sanchez Padilla, Elisabeth ^a   Dlamini, Themba ^b   Ascorra, Alexandra ^a   Rüsch Gerdes, Sabine ^c   Tefera, Zerihun Demissie ^d   Calain, Philippe ^d   de la Tour, Roberto ^d   Jochims, Frauke ^d   Richter, Elvira ^c   Bonnet, Maryline ^a  

^a EPICENTRE   (France)

^b National Tuberculosis Control Programme   (Switzerland)

^c National Reference Center for Mycobacteria   (Germany)

^d MÉDECINS SANS FRONTIÈRES   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; CAPREOMYCIN; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; ISONIAZID PLUS RIFAMPICIN; MOXIFLOXACIN; OFLOXACIN; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN;

ADULT; ARTICLE; BACTERIAL STRAIN; BACTERIUM CULTURE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; FEMALE; HEALTH CARE FACILITY; HEALTH CARE PERSONNEL; HEALTH SURVEY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANCE; MULTIDRUG RESISTANT TUBERCULOSIS; PREVALENCE; SCREENING TEST; SWAZILAND;

ADOLESCENT; ADULT; ANTIMALARIALS; CROSS-SECTIONAL STUDIES; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; HUMANS; MALE; POPULATION SURVEILLANCE; PREVALENCE; SWAZILAND; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY; YOUNG ADULT;

EID: 84856585204     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid1801.110850     Document Type: Article

References (33)

1. World Health Organization. Global tuberculosis control. Geneva: The Organization; 2010.
2. World Health Organization. The stop TB strategy: building on and enhancing DOTS to meet the TB related millennium development goals. Geneva: The Organization; 2006.
3. Badri M, Wilson D, Wood R. Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet. 2002;359:2059-64. doi:10.1016/S0140-6736(02)08904-3
4. World Health Organization. Guidelines for surveillance of drug resistance in tuberculosis. 4th edition. Geneva: The Organization; 2009.
5. World Health Organization. Towards universal access to diagnosis and treatment of multidrug-resistant and extensively drug-resistant tuberculosis by 2015. WHO progress report 2011. Geneva: The Organization; 2011.
6. Joint United Nations Programme on HIV/AIDS. AIDS epidemic update: November 2009. Geneva: The Programme; 2009.
7. World Health Organization. Global tuberculosis control: epidemiology, strategy, financing. Geneva: The Organization; 2009.
8. Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, Lalloo U, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet. 2006;368:1575-80. doi:10.1016/S0140-6736(06)69573-1
9. Ministry of Health and Social Welfare. Report of the rapid survey for the detection of extreme drug resistant tuberculosis in the Kingdom of Swaziland. Swaziland; 2008.
10. World Health Organization. Treatment of tuberculosis: guidelines. 4th ed. Geneva: The Organization; 2010.
11. World Health Organization. 7th meeting of the strategic and technical advisory group for tuberculosis (STAG-TB). Report on conclusions and recommendations. Geneva: The Organization; 2007.
12. Calver AD, Falmer AA, Murray M, Strauss OJ, Streicher EM, Hanekom M, et al. Emergence of increased resistance and extensively drug-resistant tuberculosis despite treatment adherence, South Africa. Emerg Infect Dis. 2010;16:264-71.
13. Patel KB, Belmonte R, Crowe HM. Drug malabsorption and resistant tuberculosis in HIV-infected patients. N Engl J Med. 1995;332:336-7. doi:10.1056/NEJM199502023320518
14. Suchindran S, Brouwer ES, Van RA. Is HIV infection a risk factor for multi-drug resistant tuberculosis? A systematic review. PLoS ONE. 2009;4:e5561. doi:10.1371/journal.pone.0005561
15. Wright A, Zignol M, Van DA, Falzon D, Gerdes SR, Feldman K, et al. Epidemiology of antituberculosis drug resistance 2002-07: an updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Lancet. 2009;373:1861-73. doi:10.1016/ S0140-6736(09)60331-7
16. Centers for Disease Control and Prevention. Nosocomial transmission of multidrug-resistant tuberculosis among HIV-infected persons- Florida and New York, 1988-1991. MMWR Morb Mortal Wkly Rep. 1991;40:585-91.
17. Rullán JV, Herrera D, Cano R, Moreno V, Godoy P, Peiro EF, et al. Nosocomial transmission of multidrug-resistant Mycobacterium tuberculosis in Spain. Emerg Infect Dis. 1996;2:125-9. doi:10.3201/ eid0202.960208
18. Sacks LV, Pendle S, Orlovic D, Blumberg L, Constantinou C. A comparison of outbreak- and nonoutbreak-related multidrug-resistant tuberculosis among human immunodeficiency virus-infected patients in a South African hospital. Clin Infect Dis. 1999;29:96-101. doi:10.1086/520189
19. Glynn JR, Whiteley J, Bifani PJ, Kremer K. van SD. Worldwide occurrence of Beijing/W strains of Mycobacterium tuberculosis: a systematic review. Emerg Infect Dis. 2002;8:843-9.
20. Pardini M, Niemann S, Varaine F, Iona E, Meacci F, Orru G, et al. Characteristics of drug-resistant tuberculosis in Abkhazia (Georgia), a high-prevalence area in Eastern Europe. Tuberculosis (Edinb). 2009;89:317-24. doi:10.1016/j.tube.2009.04.002
21. Affolabi D, Anyo G, Faihun F, Sanoussi N, Shamputa IC, Rigouts L, et al. First molecular epidemiological study of tuberculosis in Benin. Int J Tuberc Lung Dis. 2009;13:317-22.
22. Cowley D, Govender D, February B, Wolfe M, Steyn L, Evans J, et al. Recent and rapid emergence of W-Beijing strains of Mycobacterium tuberculosis in Cape Town, South Africa. Clin Infect Dis. 2008;47:1252-9. doi:10.1086/592575
23. Homolka S, Post E, Oberhauser B, George AG, Westman L, Dafae F, et al. High genetic diversity among Mycobacterium tuberculosis complex strains from Sierra Leone. BMC Microbiol. 2008;8:103. doi:10.1186/1471-2180-8-103
24. Kibiki GS, Mulder B, Dolmans WM, de Beer JL, Boeree M, Sam N, et al. M. tuberculosis genotypic diversity and drug susceptibility pattern in HIV-infected and non-HIV-infected patients in northern Tanzania. BMC Microbiol. 2007;7:51. doi:10.1186/1471-2180-7-51
25. Viegas SO, Machado A, Groenheit R, Ghebremichael S, Pennhag A, Gudo PS, et al. Molecular diversity of Mycobacterium tuberculosis isolates from patients with pulmonary tuberculosis in Mozambique. BMC Microbiol. 2010;10:195. doi:10.1186/1471-2180-10-195
26. Groenheit R, Ghebremichael S, Svensson J, Rabna P, Colombatti R, Riccardi F, et al. The Guinea-Bissau family of Mycobacterium tuberculosis complex revisited. PLoS ONE. 2011;6:e18601. doi:10.1371/ journal.pone.0018601
27. Johnson R, Warren RM, van der Spuy GD, Gey van Pittius NC, Theron D, Streicher EM, et al. Drug-resistant tuberculosis epidemic in the Western Cape driven by a virulent Beijing genotype strain. Int J Tuberc Lung Dis. 2010;14:119-21.
28. Strategic and Technical Advisory Group for Tuberculosis (STAGTB). Report of the ninth meeting. Geneva: The Organization; 2009.
29. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. Emergency update. Geneva: The Organization; 2008.
30. Boehme CC, Nabeta P, Hillemann D, Nicol MP, Shenai S, Krapp F, et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med. 2010;363:1005-15. doi:10.1056/ NEJMoa0907847
31. Cohen T, Colijn C, Finklea B, Wright A, Zignol M, Pym A, et al. Are survey-based estimates of the burden of drug resistant TB too low? Insight from a simulation study. PLoS ONE. 2008;3:e2363. doi:10.1371/journal.pone.0002363
32. Cohen T, Colijn C, Wright A, Zignol M, Pym A, Murray M. Challenges in estimating the total burden of drug-resistant tuberculosis. Am J Respir Crit Care Med. 2008;177:1302-6. doi:10.1164/ rccm.200801-175PP
33. Ben Amor Y, Nemser B, Singh A, Sankin A, Schluger N. Underreported threat of multidrug-resistant tuberculosis in Africa. Emerg Infect Dis. 2008;14:1345-52. doi:10.3201/eid1409.061524